Analyst Ratings For Travere Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have recently updated their ratings for Travere Therapeutics (NASDAQ:TVTX), with a majority showing bullish sentiment. The average 12-month price target has increased by 16.7% to $18.38. Travere Therapeutics has shown significant revenue growth but faces challenges with high debt and low returns on equity and assets.
September 06, 2024 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Travere Therapeutics has received predominantly bullish analyst ratings, with a significant increase in the average price target. The company shows strong revenue growth but faces financial challenges with high debt and low returns.
The majority of analysts have raised their ratings and price targets for Travere Therapeutics, indicating positive sentiment. The increase in the average price target suggests expectations of stock price appreciation. However, the company's financial metrics, such as high debt and low returns, may temper the bullish outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100